Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 2/2020

02.05.2020 | Pediatric Bladder Dysfunction (J Thomas and D Clayton, Section Editors)

Valve Bladder Syndrome Associated with Posterior Urethral Valves: Natural History, Work-up, and Management

verfasst von: Ernest Pang Chan, Peter Zhan Tao Wang, Sumit Dave

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review focuses on the diagnosis, evaluation, and management of valve bladder syndrome (VBS) following initial treatment of posterior urethral valves (PUV). Based on current literature, we discuss the effect of PUV management in VBS and investigate the role of medications, catherization, surgery, and novel interventions.

Recent Findings

The current initial management of PUV involves valve ablation. Cutaneous urinary diversions are secondary options based on patient characteristics, PUV severity, and response to catheter drainage. VBS can independently occur as a consequence of PUV due to reduced nephron endowment leading to renal tubular dysfunction and polyuria, high bladder filling pressures secondary to a non-compliant bladder, and poor bladder emptying due to bladder neck hypertrophy. Options to mitigate the risk of upper tract deterioration include behavioral modifications and medical therapy (anticholinergics or alpha-blockers), bladder neck incision, clean intermittent catheterization and overnight catheter drainage, or more invasive approaches such as botulinum toxin injections and creation of a Mitrofanoff channel. Several experimental therapies to attenuate bladder fibrosis are currently under investigation.

Summary

The management of VBS starts with initial management of PUV and is subsequently dependent on the evolving bladder filling dynamics and bladder neck hypertrophy affecting bladder filling and emptying. This requires a pre-emptive management protocol to identify VBS in boys with PUV to prevent renal damage using various therapeutic interventions. The lack of prospective studies to investigate effectiveness of available therapeutic options to treat VBS limits the development of an evidence-based approach for severity-based management of PUV-associated VBS.
Literatur
1.
Brownlee E, Wragg R, Robb A, Chandran H, Knight M, McCarthy L, et al. Current epidemiology and antenatal presentation of posterior urethral valves: outcome of BAPS CASS National Audit. J Pediatr Surg. 2019;54:318–21.CrossRef
2.
Heikkil J, Holmberg C, Kyllönen L, et al. Long-term risk of end stage renal disease in patients with posterior urethral valves. J Urol. 2011;186:2392–6.CrossRef
3.
Robyr R, Benachi A, Daikha-Dahmane F, Martinovich J, Dumez Y, Ville Y. Correlation between ultrasound and anatomical findings in fetuses with lower urinary tract obstruction in the first half of pregnancy. Ultrasound Obstet Gynecol. 2005;25:478–82.CrossRef
4.
Mitchell ME. Persistent ureteral dilatation following valve ablation. Dialogue Pediatr Urol. 1982;2.
5.
Kerfoot BP, Mitchell ME, Novick AC. Grappling with the evaluation of clinical competencies: a view from the residency review committee for urology. Urology. 2002;60:223–4.CrossRef
6.
Androulakakis PA, Karamanolakis DK, Tsahouridis G, Stefanidis AA, Palaeodimos I. Myogenic bladder decompensation in boys with a history of posterior urethral valves is caused by secondary bladder neck obstruction? BJU Int. 2005;96:140–3.CrossRef
7.
Koff SA, Mutabagani KH, Jayanthi VR. The valve bladder syndrome: pathophysiology and treatment with nocturnal bladder emptying. J Urol. 2002;167:291–7.CrossRef
8.
•• Fusco F, Creta M, De Nunzio C, et al. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018;18:15 Fusco et al. review 36 studies to describe a three-stage model of bladder wall remodeling, which includes an initial hypertrophy phase, subsequent compensation phase, and a later decompensation. The changes associated with these phases involve multiple signaling pathways that offer potential targets for intervention and future therapies for patients with PUV. CrossRef
9.
Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75:1145–52.CrossRef
10.
Lopez Pereira P, Martinez Urrutia MJ, Espinosa L, Lobato R, Navarro M, Jaureguizar E. Bladder dysfunction as a prognostic factor in patients with posterior urethral valves. BJU Int. 2002;90:308–11.CrossRef
11.
Glassberg KI, Combs A. The valve bladder syndrome: 35+ years later. J Urol. 2016;196:16–7.CrossRef
12.
Riah L, Belhaj K, Lmidmani F, el Fatimi A, el Kettani Y, el Ayoubi M, et al. Urodynamic profile of voiding disorders persisting after treatment of posterior urethral valve. Prog Urol. 2015;25:217–23.CrossRef
13.
Lopez Pereira P, Martinez Urrutia MJ, Espinosa L, Jaureguizar E. Long-term consequences of posterior urethral valves. J Pediatr Urol. 2013;9:590–6.CrossRef
14.
Ghanem MA, Wolffenbuttel KP, De Vylder A, et al. Long-term bladder dysfunction and renal function in boys with posterior urethral valves based on urodynamic findings. J Urol. 2004;171:2409–12.CrossRef
15.
• Niyogi A, Lumpkins K, Robb A, et al. Cystometrogram appearance in PUV is reliably quantified by the shape,wall, reflux and diverticuli (SWRD) score, and presages the need for intervention. J Pediatr Urol. 2017;13:265.e1–6 Niyogi et al. identify that use of the SWRD score is reliable and reproducible, and correlates with bladder outcome and videourodynamic assessment in boys with PUV. Blinded assessors determined SWRD scores of PUV bladders, which were then correlated with clinical outcome. Highwer SWRD scores were associated with poorly compliant bladders, severe detrusor overactivty, and high intravesical pressure. CrossRef
16.
Babu R, Kumar R. Early outcome following diathermy versus cold knife ablation of posterior urethral valves. J Pediatr Urol. 2013;9:7–10.CrossRef
17.
Mallya A, Karthikeyan VS, Vijayganapathy S, et al. Urodynamic profile in posterior urethral valve patients following fulguration: does age at fulguration matter? Indian J Urol. 2018;34:278–82.CrossRef
18.
• Sharifiaghdas F, Mirzaei M, Nikravesh N. Can transient resting of the bladder with vesicostomy reduce the need for a major surgery in some patients? J Pediatr Urol. 2019;15:379.e1–8 Sarifiaghdas et al. evaluated the long-term outcomes of patients who had undergone cutaneous vesicostomy over an 11-year period. They identified that vesicostomy was associated with reduction in febrile urinary tract infections, protect the upper tracts, and reduce the need for major surgery without decreasing the bladder capacity. These results suggest against the theory that vesicostomy results in permanent destabilization of the bladder long-term. CrossRef
19.
20.
21.
Smith GHH, Canning DA, Schulman SL, Snyder HM 3rd, Duckett JW. The long-term outcome of posterior urethral valves treated with primary valve ablation and observation. J Urol. 1996;155:1730–4.CrossRef
22.
Jaureguizar E, Lopez Pereira P, Martinez Urrutia MJ, et al. Does neonatal pyeloureterostomy worsen bladder function in children with posterior urethral valves? J Urol. 2000;164:1031–4.CrossRef
23.
Gastol P, Skobejko-Wlodarska L, Baka-Ostrowska M. Temporary high urinary diversion with valves incision in the same procedure in treatment of the boys with posterior urethral valves – 10 years after. J Pediatr Urol. 2010;6:S49.CrossRef
24.
Podestá M, Ruarte AC, Gargiulo C, et al. Bladder function associated with posterior urethral valves after primary valve ablation or proximal urinary diversion in children and adolescents. J Urol. 2002;168:1830–5.CrossRef
25.
Podestá ML, Ruarte A, Gargiulo C, Medel R, Castera R. Urodynamic findings in boys with posterior urethral valves after treatment with primary valve ablation or vesicostomy and delayed ablation. J Urol. 2000;164:139–44.CrossRef
26.
• Chua ME, Ming JM, Carter S, et al. Impact of adjuvant urinary diversion versus valve ablation alone on progression from chronic to end stage renal disease in posterior urethral valves: a single institution 15-year time-to-event analysis. J Urol. 2018;199:824–30 Chua et al. compare the long-term renal outcomes of boys with PUV who underwemt adjuvant urinary diversion versus valve ablation alone. They identify that urinary diversion following valve ablation may temporarily delay progression to ESRD, but no long-term benefit was noted from diversion in the ultimate incidence of ESRD. The findings of this study suggest that predilection for progression to ESRD occurs antenatally and may be difficult to impede postnatally. CrossRef
27.
• DJ ML, Szymanski KM, Gong E, et al. Renal replacement therapy and intermittent catheterization risk in posterior urethral valves. Pediatrics. 2019;143. https://​doi.​org/​10.​1542/​peds.​2018-2656McLeod et al. identify clinical variables associated with the risk of renal replacement therapy and clean intermittent catheterization in a large multicenter cohort study. Their findings indicate that risk of RRT and CIC recommendations increases with age, and that serum nadir creatinine at 1 year (SNC1) strongly predicts need for RRT. This study allows for risk stratification for RRT by 10 years based on SNC1 and identifies that more than one-quarter of boys with PUV will require CIC by 10 years of age.
28.
King T, Coleman R, Parashar K. Mitrofanoff for valve bladder syndrome: effect on urinary tract and renal function. J Urol. 2014;191:1517–22.CrossRef
29.
Nguyen MT, Pavlock CL, Zderic SA, et al. Overnight catheter drainage in children with poorly compliant bladders improves post-obstructive diuresis and urinary incontinence. In: Journal of Urology. Lippincott Williams and Wilkins, 2005, pp. 1633–1636.
30.
Singh SK, Sharma V, Singh A. Urodynamic changes after valve fulguration alone and valve fulguration with bladder neck incision. J Indian Assoc Pediatr Surg. 2019;24:31–5.CrossRef
31.
Keihani S, Kajbafzadeh A-M, Kameli SM, Abbasioun R. Long-term impacts of concurrent posterior urethral valve ablation and bladder neck incision on urinary continence and ejaculation. Urology. 2017;99:278–80.CrossRef
32.
Hennus PML, Hoenjet E, Kieft JH, et al. The long-term effect of superficial bladder neck incision on ejaculation and incontinence in boys with primary and secondary bladder neck obstruction. Front Pediatr. 2017;5:152.CrossRef
33.
Sarin YK, Sinha S. Efficacy of bladder neck incision on urodynamic abnormalities in patients with posterior urethral valves. Pediatr Surg Int. 2013;29:387–92.CrossRef
34.
Casey JT, Hagerty JA, Maizels M, Chaviano AH, Yerkes E, Lindgren BW, et al. Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol. 2012;188:1516–20.CrossRef
35.
Abraham MK, Nasir ARA, Sudarsanan B, Puzhankara R, Kedari PM, Unnithan GR, et al. Role of alpha adrenergic blocker in the management of posterior urethral valves. Pediatr Surg Int. 2009;25:1113–5.CrossRef
36.
37.
Mokhless I, Zahran AR, Saad A, Yehia M, Youssif ME. Effect of Botox injection at the bladder neck in boys with bladder dysfunction after valve ablation. J Pediatr Urol. 2014;10:899–904.CrossRef
38.
Wright AE, Wragg R, Lopes J, Robb A, McCarthy L. Prediction of need for intervention in posterior urethral valves: use of urine osmolality. J Pediatr Surg. 2018;53:316–20.CrossRef
39.
Jesus LE, Pippi Salle JL. Pre-transplant management of valve bladder: a critical literature review. J Pediatr Urol. 2015;11:5–11.CrossRef
40.
Al-Saikan B, Ding J, Tredget E, et al. Benefits of mesenchymal stem cells after partial bladder outlet obstruction. Can Urol Assoc J. 2016;10:E1–6.CrossRef
41.
Wiafe B, Adesida AB, Churchill T, et al. Mesenchymal stem cell therapy inhibited inflammatory and profibrotic pathways induced by partial bladder outlet obstruction and prevented high-pressure urine storage. J Pediatr Urol. 2019;15:254.e1–254.e10.CrossRef
42.
Maciejewski CC, Tredget EE, Metcalfe PD. Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model. Neurourol Urodyn. 2015;34:286–91.CrossRef
43.
Schröder A, Kirwan TP, Jiang JX, Aitken KJ, Bägli DJ. Rapamycin attenuates bladder hypertrophy during long-term outlet obstruction in vivo: tissue, matrix and mechanistic insights. J Urol. 2013;189:2377–84.CrossRef
44.
Jiang X, Chen Y, Zhu H, et al. Sodium tanshinone IIA sulfonate ameliorates bladder fibrosis in a rat model of partial bladder outlet obstruction by inhibiting the TGF-β/Smad pathway activation. PLoS One. 2015;10:e0129655.CrossRef
45.
Iguchi N, Dönmez Mİ, Malykhina AP, Carrasco A Jr, Wilcox DT. Preventative effects of a HIF inhibitor, 17-DMAG, on partial bladder outlet obstruction-induced bladder dysfunction. Am J Physiol Ren Physiol. 2017;313:F1149–60.CrossRef
46.
Comiter C, Phull HS. Angiotensin II type 1 (AT-1) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model. BJU Int. 2012;109:1841–6.CrossRef
Metadaten
Titel
Valve Bladder Syndrome Associated with Posterior Urethral Valves: Natural History, Work-up, and Management
verfasst von
Ernest Pang Chan
Peter Zhan Tao Wang
Sumit Dave
Publikationsdatum
02.05.2020
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 2/2020
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-020-00577-1

Weitere Artikel der Ausgabe 2/2020

Current Bladder Dysfunction Reports 2/2020 Zur Ausgabe

Pediatric Bladder Dysfunction (J Thomas and D Clayton, Section Editors)

Is Urinary Retention Following Extravesical Ureteral Reimplantation Still a Concern?

Neurogenic Bladder (C Powell, Section Editor)

Opioid Use in Urologic Practice

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Predicting Upper Urinary Tract Risk in the Neurogenic Bladder Patient

BPS/Interstitial Cystitis (D Castro-Diaz and Y Igawa, Section Editors)

Sacral Neuromodulation in the Management of Bladder Pain Syndrome/Interstitial Cystitis

Stress Incontinence and Prolapse (WS Reynolds, Section Editor)

Vaginal Mesh Survivorship

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise